NovoCure Ltd — Director's Dealing 2022

Sep 13, 2022

SEC Form 4/A — Form 4/A

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-09-08

Reporting Person: Leonard Frank X (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-08	Ordinary Shares	S	6754	$81.48	Disposed	77396	Direct

Footnotes

F1: Amending original Form 4 filed on September 12, 2022 to add additional transaction inadvertently omitted.

F2: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard.